Patient-derived tumor models are attractive tools to repurpose drugs for ovarian cancer treatment: pre-clinical updates.
Patient-Derived Xenografts of High-Grade Serous Ovarian Cancer Subtype as a Powerful Tool in Pre-Clinical Research.
The role of distinct BRD4 isoforms and their contribution to high-grade serous ovarian carcinoma pathogenesis.
Multi-kinase targeted therapy as a promising treatment strategy for ovarian tumors expressing sfRon receptor.
Switching the intracellular pathway and enhancing the therapeutic efficacy of small interfering RNA by auroliposome.
